Supplementary Table S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Authors
Evgenia Glogova
Thomas Klingebiel (ORCID: https://orcid.org/0000-0001-5726-9092)
Supplementary Table S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Evgenia Glogova, Thomas Klingebiel, Ruth Lydia Ladenstein, Dominique Valteau‐Couanet et al.
Topics
Neuroblastoma Research and Treatments
article
Supplementary Table S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Evgenia Glogova, Thomas Klingebiel, Ruth Lydia Ladenstein, Dominique Valteau‐Couanet, Holger N. Lode, Ulrike Pötschger, Nikolai Siebert, Jean Michon, Juliet C. Gray, Adela Cañete, Roberto Luksch, Isaac Yaniv, Sascha Troschke‐Meurer, Cormac Owens, Shifra Ash, Carla Manzitti, Alberto Garaventa, Hans Loibner, John W. Anderson